Class ICompleted

UMOVY ACIDO HIALURONICO recall

FDA recall D-0493-2025 · initiated May 21, 2025

Most serious — a reasonable probability that use will cause serious harm or death.

Why it was recalled

Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.

Details

Product: UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal. C.P, UPC 7503046054134
Recalling company: Umary-USA.com
Classification: Class I
Status: Completed
Type: Voluntary: Firm initiated
Distribution: U.S. Nationwide via internet.
Initiated: May 21, 2025
FDA report date: Jun 25, 2025

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0493-2025 ↗

← All drug recalls